48 results about "Cytogenetics" patented technology

Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.

Disclosed is a method for using a first polar body and a second polar body as well as a single-cell embryo to carry out whole-genome non-exponential amplification and high-throughput genome sequencing, so as to perform preimplantation genetic diagnosis for genetic disease and testing for pathogenic genes causing repeated miscarriages. The method of the present invention comprises the following steps: (1) obtaining oocytes and embryos, and carrying out separation and genome amplification of first and second polar bodies and single-cell embryos; (2) establishing a genome sequencing library and sequencing, and carrying out bioinformatic analysis of the genome to obtain a gene spectrum and information concerning the number of copies of chromosomes and fragments thereof; (3) determining the chromosome ploidy of the polar bodies and embryos as well as information concerning defects, replication and point mutation in the chromosome fragments; (4) selecting normal or suitable embryos for implantation.

The invention relates to the field of molecular medicine, and in particular relates to a gene chip for leukemia diagnosis and treatment. The chip contains oligonucleotide probes with sequences in SEQ ID NO:1-137. The chip has the following beneficial effects that: the actual demands in the blood system tumor diagnosis and treatment process in China are met; the gene chip is customized by screening key indicators in examination indicators in leukemia morphology, immunology, cytogenetics and molecular biology; and the multifunctional gene chip integrates early diagnosis, early warning, prevention and diagnosis and treatment of leukemia and can improve the individual diagnosis efficiency and treatment effect of leukemia, shorten the length of stay, reduce the medical expenses and improve the technical levels of the primary-level medical and health institutions.

The invention relates to an identification method for an amblyopyrum muticum chromosome in a wheat genome, and belongs to the field of cell genetics. The identification method comprises the following steps: using Oligo-pTa535-1, Oligo-pSc119.2-1 and (GAA)8 as probes to perform fluorescence in-situ hybridization (FISH) on innovative idioplasmatic chromosome of wheat-amblyopyrum muticum, comparing with a bi-color FISH standard drawing of 42 chromosomes of the wheat, and at last obtaining hybridization signals and karyotype information of seven pairs of chromosomes of amblyopyrum muticum. According to the identification method disclosed by the invention, Oligo-pTa535-1, Oligo-pSc119.2-1 and (GAA)8 are used as the probes to perform fluorescence in-situ hybridization on chromosomes of wheat-amblyopyrum muticum filial generation; the results are respectively compared with the wheat-amblyopyrum muticum innovative idioplasmatic chromosome hybridization signals and karyotype information of the amblyopyrum muticum chromosomes, and at last the identification is completed. The invention provides the novel method for detecting the amblyopyrum muticum chromosome in the wheat genome.

The invention discloses a DNA array for leukemia chromosome aberration high-throughput targeted capture detection. In the DNA array, the contained probe is capable of specific targeted capture of 18 genes involved in 37 chromosome aberrations. A sample and the DNA array are hybridized, chromosome aberration involved gene sequences are captured targetedly, then the captured sequences are subjected to sequencing, the sequencing result is analyzed to screen out the existent chromosome aberration type. The probe contained in the DNA array can specifically bind the 18 genes involved in 37 chromosome aberrations so as to realize rapid screening of leukemia related chromosome translocation. By chip inspection, a plurality of samples can be detected at a time, and the cost is low. For the to-be-detected 37 sites, the accuracy is close to 100%. And cytogenetics professionals are not needed for interpretation of the result.

The invention provides a blood tumor chromosome karyotype automatic analysis method. The method comprises the following steps: S1, acquiring a chromosome image; s2, preprocessing the acquired chromosome image; s3, segmenting the chromosome according to the chromosome image obtained by preprocessing; s4, extracting characteristic parameters of the segmented chromosomes; and S5, classifying the chromosomes according to an extraction result of the characteristic parameters, and completing the automatic analysis of the karyotype of the chromosome. The invention further provides a blood tumor chromosome karyotype automatic analysis system, intelligence of chromosome karyotype analysis is achieved; the cytogenetics experiment technology is combined with advanced technologies such as image processing and image analysis, the diagnosis accuracy is greatly improved, the detection time is shortened, the detection efficiency is greatly improved, and the technical defects of low intelligent degree and low detection efficiency in the prior art are effectively overcome.

The invention discloses novel application of an ankyrin repeat domain-containing 13A gene and/or a protein encoded by the same. An acute myeloid leukemia (AML) diagnosis and prognosis related molecular marker is screened to obtain an ankyrin repeat domain-containing 13A gene(ANKRD13A) closely related to AML patient prognosis; the high expression of ANKRD13A in the body of an AML patient warns poorprognosis; the ANKRD13A can be used as an independent factor for influencing the prognosis of the AML patient; the ANKRD13A is related to the FAB typing and the cytogenetics risk stratification of the AML patient; and the ANKRD13A may participate in the disease progression of AML through a variety of pathways. The ANKRD13A can be used for preparing a therapeutic drug or a prognosis detection reagent for the acute myeloid leukemia.

The invention belongs to the field of plant cytogenetics, and discloses an in-situ hybridization detection method for identifying and authenticating aegilops comosa M chromosome in wheat background. The detection method comprises the following steps of performing double-color FISH (fluorescence in situ hybridization) on the chromosome preparation of tested material by polynucleotides Oligo-pTa535.1-1 and Oligo-pSc119.2-1, using (GAA)8 as a probe, performing secondary FISH on the chromosome of same cell by an elution double-color FISH signal, and authenticating the aegilops comosa chromosome in the wheat background. The method has the advantages that the aegilops comosa chromosome in a wheat chromosome group is quickly and effectively identified, the application of the polynucleotide probe in triticeae species is widened, a detection method is provided for the authenticating of new variety resource of distant hybridization of wheat-aegilops comosa, and a simple and effective cytogenetic authenticating method is provided for transferring the powdery mildew resistance gene on the aegilops comosa chromosome into the wheat.

Staining nucleotides within chromosomes is an important technique used in cytogenetics to produce a visible karyotype by staining condensed chromosomes. Such techniques are useful, for example, in identifying genetic diseases through the photographic representation of the entire chromosome complement. Prior to the steps of selective dissolving and staining of nucleotides within the chromosomes an aging step is performed to increase the selective solubility between different nucleotides. Within the prior art this aging step is a time consuming process taking several days. Accordingly, it would be beneficial to provide a staining pretreatment method which can be performed in a short period of time.

The invention relates to a novel application of gamma-secretase activated protein gene and/or protein coded by gamma-secretase activated protein gene. According to the application disclosed by the invention, by screening acute myelogenous leukemia (AML) prognosis related molecular markers, the screened gamma-secretase activated protein gene (GSAP) is closely related to the prognosis of acute myelogenous leukemia patients; the high expression of the GSAP prompts that the prognosis of the acute myelogenous leukemia patient is poor; the GSAP is related to FAB typing and cytogenetics risk stratification of an acute myelogenous leukemia patient; and the GSAP may participate in the disease progress of acute myelogenous leukemia through various ways such as PI3K-AKT, TLR and the like. The GSAP is used for preparing a treatment drug or a diagnostic reagent and a prognosis detection reagent for acute myelogenous leukemia.

The invention provides a preparation method of an RBM5 FISH probe for lung cancer detection. The RBM5 FISH probe can be applied to early diagnosis of lung cancer, can significantly improve the diagnosis accuracy when combined with an existing molecular probe, is applicable to multiple types of detection samples, such as paraffin sections, cell drops, cell smears and sputum cells, and can be applied to detection of various clinical samples. A kit can be prepared from the RBM5 FISH probe, the RBM5 FISH probe can be applied to fields of tumor biology, cytogenetics and the like, and comprehensive assessment on relations between various molecular markers and development of the lung cancer is facilitated.

Provided herein are methods and related systems for controlling droplet spreading on a surface, including droplets in which a biological component is suspended. A biological solution is provided as a droplet to a surface. Interference fringes generated by the droplet on the surface are imaged, wherein the imaging is over a time course during which the droplet spreads on the surface. A droplet parameter is determined from the imaging step and a process parameter controlled to obtain an interference fringe pattern corresponding to a desired droplet parameter. In this manner, well-controlled droplet spreading is achieved, which is important in a range of applications, including assays that rely on good metaphase spreading.

The invention discloses a method for preparing a pelochelys bibroni chromosome specimen by using peripheral blood cells, and belongs to the field of cytogenetics. Peripheral blood of a pelochelys bibroni is collected, and a pelochelys bibroni chromosome metaphase specimen which is convenient to observe and clear in image is prepared through the steps of blood cell culture, colchicine treatment, staining and slide preparation and the like. According to the method of the invention, the problem of large damage to animals in an existing aquatic animal chromosome specimen preparation method is solved, non-damage sampling is realized, only a small amount of peripheral blood of the sample needs to be collected, and the influence on the living state of the animals is small. The slide preparation method is simple and rapid; the metaphase of the pelochelys bibroni chromosome can be obtained 72 hours after blood sampling, observation is facilitated, and a beneficial tool is provided for further developing pelochelys bibroni genome and evolution related research and realizing more sufficient protection of the pelochelys bibroni .

The invention discloses a biological tissue photoacoustic circulating tumor cell detection and diagnosis device. The device is provided with a high-frequency pulse laser, a microscope and a ultrasonic probe, and a detected object is arranged between the microscope and the ultrasonic probe so that laser generated by the high-frequency pulse laser can be focused on the detected object through the microscope. The invention further discloses a detection and diagnosis method of the detection and diagnosis device. Due to the adoption of the technical scheme, the defect that fluorescent markers interfere in the biological tissue physiological environment and have cytotoxicity on normal blood cells and lymphocytes is overcome. Non-invasive detection is achieved, haemospasia is avoided, and marking is not needed; data difference between animal individuals is avoided, and the number of animals needed during an animal experiment is greatly reduced; the application range is wide, and the biological tissue photoacoustic circulating tumor cell detection and diagnosis device can be widely applied to the immunology, hematology, oncology, cytobiology, cytogenetics, biochemistry, clinical medicine and basic medicine research fields; the device is simple in structure, convenient to operate and high in safety.

The invention discloses a marker for auxiliary diagnosis, prognosis diagnosis or risk stratification of acute myeloid leukemia and application thereof. After multiple experiments, the patentee finds that compared with a normal person, the expression quantity of ARF3 in bone marrow of an acute myeloid leukemia (hereinafter referred to as AML) patient is remarkably increased, which indicates that the ARF3 gene can be used as an auxiliary diagnosis marker of AML; meanwhile, the patentee also finds that the expression level of the ARF3 gene is significantly related to the prognosis of the AML patient, and the AML patient with high ARF3 expression has poorer overall survival and event-free survival, which prompts that the prognosis is poor, especially in a risk group in cytogenetics risk stratification; and therefore, the ARF3 gene can be used as a marker for prognostic diagnosis or risk stratification of AML.

The invention discloses a marker for early diagnosis, risk stratification and prognosis risk stratification of acute myelogenous leukemia and application of the marker. A patentee finds that compared with a normal person, the expression quantity of SSBP4 in bone marrow of an acute myelogenous leukemia (hereinafter referred to as AML) patient is remarkably increased, meanwhile, the expression level of the SSBP4 gene is remarkably related to prognosis of the AML (non-APL) patient, and the AML (non-APL) patient with high SSBP4 expression has poorer overall survival and event-free survival, which prompts that the prognosis is poor; high expression of SSBP4 also prompts poor prognosis in a risk group (cytogenetics risk stratification) in AML, and the high expression of SSBP4 particularly plays a very important role in prompting early death of patients; the SSBP4 gene can be used as a marker for early diagnosis, risk stratification and prognosis risk stratification of acute myelogenous leukemia.